ID

21429

Description

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00299182

Link

https://clinicaltrials.gov/show/NCT00299182

Keywords

Versions (1)
  1. 2017-04-21 2017-04-21 -
Uploaded on

21 april 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Lymphoma NCT00299182

English

Eligibility Lymphoma NCT00299182

1 forms  
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00299182
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients with a diagnosis of previously untreated aggressive non-hodgkin's lymphoma, including patients with mantle cell lymphoma, who will be or are receiving treatment with r-hypercvad and r-ara-c/mtx. patients in whom rituximab is not used, due to contraindication, will be eligible. patients whose therapy was switched to (r)hyper-cvad after initial treatment with (r)chop, because of aggressive disease will also be eligible for the study.
Description

Aggressive non-hodgkin's lymphoma, therapy with r-hypercvad and r-ara-c/mtx, contraindication to rituximab, switch to (r)hyper-CVAD

Data type

boolean

Alias
UMLS CUI [1]
C1332225
UMLS CUI [2]
C1881081
UMLS CUI [3,1]
C0393022
UMLS CUI [3,2]
C0522473
UMLS CUI [4,1]
C1742845
UMLS CUI [4,2]
C0392747
2. patients age >/= 18 years.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
3. karnofsky performance scale >/= 70.
Description

Karnofsky performance scale

Data type

boolean

Alias
UMLS CUI [1]
C0206065
4. adequate hematologic (anc >/= 1000/mm(3), platelet count >/= 100,000/mm(3) and hgb >/= 8gm/dl), renal (serum creatinine < 2mg/dl), and hepatic functions (total bilirubin </= 2 times, serum glutamate pyruvate transaminase (sgpt) or serum glutamate oxaloacetate transaminase (sgot) </= 3 times the upper limit of the respective normal range).
Description

ANC, platelet count, hemoglobin measurement, creatinine measurement, total bilirubin, sgpt

Data type

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2]
C0005821
UMLS CUI [3]
C0019046
UMLS CUI [4]
C0201976
UMLS CUI [5]
C0201913
UMLS CUI [6]
C0201836
UMLS CUI [7]
C0201899
5. patients (male and female) with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization) must use adequate birth control.
Description

Contraceptive method

Data type

boolean

Alias
UMLS CUI [1]
C0700589
6. institutional review board (irb)-approved signed informed consent.
Description

Informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. pregnant or lactating women.
Description

Gynaecological status

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. history of central nervous system (cns) involvement.
Description

CNS involvement

Data type

boolean

Alias
UMLS CUI [1]
C0449389
3. co-morbid medical or psychiatric illnesses that preclude treatment with intense dose chemotherapy.
Description

Comorbidity

Data type

boolean

Alias
UMLS CUI [1]
C0009488
4. patients with history of deep vein thrombosis (dvt) or pulmonary embolus.
Description

Deep vein thrombosis or pulmonary embolus

Data type

boolean

Alias
UMLS CUI [1]
C0149871
UMLS CUI [2]
C0034065
5. history of any platelet disorders including idiopathic thrombocytopenic purpura (itp), thrombotic thrombocytopenic purpura (ttp) or bleeding disorders.
Description

Platelet or bleeding disorders

Data type

boolean

Alias
UMLS CUI [1]
C0005818
UMLS CUI [2]
C0005779
6. prior surgery or radiation therapy (rt) within 2 weeks of study entry.
Description

Prior Surgery or Radiation

Data type

boolean

Alias
UMLS CUI [1]
C0744961
UMLS CUI [2]
C0279134
7. patients with significant cardiac disease (new york heart association (nyha) class iii or iv), dysrrhythmia, or recent history of myocardial ischemia (mi) or ischemia, transient ischemic attack or cerebrovascular accident (cva) within the previous 6 months of study entry.
Description

NYHA, arrhythmia, myocardial ischemia, cerebrovascular accident

Data type

boolean

Alias
UMLS CUI [1]
C1275491
UMLS CUI [2]
C0003811
UMLS CUI [3]
C0027051
UMLS CUI [4]
C0038454
Back to the top of the page

Similar models

Eligibility Lymphoma NCT00299182

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00299182
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Aggressive non-hodgkin's lymphoma, therapy with r-hypercvad and r-ara-c/mtx, contraindication to rituximab, switch to (r)hyper-CVAD
Item
1. patients with a diagnosis of previously untreated aggressive non-hodgkin's lymphoma, including patients with mantle cell lymphoma, who will be or are receiving treatment with r-hypercvad and r-ara-c/mtx. patients in whom rituximab is not used, due to contraindication, will be eligible. patients whose therapy was switched to (r)hyper-cvad after initial treatment with (r)chop, because of aggressive disease will also be eligible for the study.
boolean
C1332225 (UMLS CUI [1])
C1881081 (UMLS CUI [2])
C0393022 (UMLS CUI [3,1])
C0522473 (UMLS CUI [3,2])
C1742845 (UMLS CUI [4,1])
C0392747 (UMLS CUI [4,2])
Age
Item
2. patients age >/= 18 years.
boolean
C0001779 (UMLS CUI [1])
Karnofsky performance scale
Item
3. karnofsky performance scale >/= 70.
boolean
C0206065 (UMLS CUI [1])
ANC, platelet count, hemoglobin measurement, creatinine measurement, total bilirubin, sgpt
Item
4. adequate hematologic (anc >/= 1000/mm(3), platelet count >/= 100,000/mm(3) and hgb >/= 8gm/dl), renal (serum creatinine < 2mg/dl), and hepatic functions (total bilirubin </= 2 times, serum glutamate pyruvate transaminase (sgpt) or serum glutamate oxaloacetate transaminase (sgot) </= 3 times the upper limit of the respective normal range).
boolean
C0948762 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0201913 (UMLS CUI [5])
C0201836 (UMLS CUI [6])
C0201899 (UMLS CUI [7])
Contraceptive method
Item
5. patients (male and female) with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization) must use adequate birth control.
boolean
C0700589 (UMLS CUI [1])
Informed consent
Item
6. institutional review board (irb)-approved signed informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Gynaecological status
Item
1. pregnant or lactating women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
CNS involvement
Item
2. history of central nervous system (cns) involvement.
boolean
C0449389 (UMLS CUI [1])
Comorbidity
Item
3. co-morbid medical or psychiatric illnesses that preclude treatment with intense dose chemotherapy.
boolean
C0009488 (UMLS CUI [1])
Deep vein thrombosis or pulmonary embolus
Item
4. patients with history of deep vein thrombosis (dvt) or pulmonary embolus.
boolean
C0149871 (UMLS CUI [1])
C0034065 (UMLS CUI [2])
Platelet or bleeding disorders
Item
5. history of any platelet disorders including idiopathic thrombocytopenic purpura (itp), thrombotic thrombocytopenic purpura (ttp) or bleeding disorders.
boolean
C0005818 (UMLS CUI [1])
C0005779 (UMLS CUI [2])
Prior Surgery or Radiation
Item
6. prior surgery or radiation therapy (rt) within 2 weeks of study entry.
boolean
C0744961 (UMLS CUI [1])
C0279134 (UMLS CUI [2])
NYHA, arrhythmia, myocardial ischemia, cerebrovascular accident
Item
7. patients with significant cardiac disease (new york heart association (nyha) class iii or iv), dysrrhythmia, or recent history of myocardial ischemia (mi) or ischemia, transient ischemic attack or cerebrovascular accident (cva) within the previous 6 months of study entry.
boolean
C1275491 (UMLS CUI [1])
C0003811 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0038454 (UMLS CUI [4])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial